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ABSTRACT
Objectives To assess the long term clinical and cost
effectiveness of the diabetes education and self
management for ongoing and newly diagnosed
(DESMOND) intervention compared with usual care in
people with newly diagnosed type 2 diabetes.
DesignWe undertook a cost-utility analysis that used
data from a 12 month, multicentre, cluster randomised
controlled trial and, using the Sheffield type 2 diabetes
model, modelled long term outcomes in terms of use of
therapies, incidence of complications, mortality, and
associated effect on costs and health related quality of
life. A further cost-utility analysis was also conducted
using current “real world” costs of delivering the
intervention estimated for a hypothetical primary
care trust.
Setting Primary care trusts in the United Kingdom.
Participants Patients with newly diagnosed
type 2 diabetes.
Intervention A six hour structured group education
programme delivered in the community by two
professional healthcare educators.
Main outcome measures Incremental costs and quality
adjusted life years (QALYs) gained.
ResultsOn the basis of the data in the trial, the estimated
mean incremental lifetime cost per person receiving the
DESMOND intervention is £209 (95% confidence interval
−£704 to £1137; €251, −€844 to €1363; $326, −$1098 to
$1773), the incremental gain in QALYs per person is
0.0392 (−0.0813 to 0.1786), and the mean incremental
cost per QALY is £5387. Using “real world” intervention
costs, the lifetime incremental cost of the DESMOND
intervention is £82 (−£831 to £1010) and the mean
incremental cost per QALY gained is £2092. A
probabilistic sensitivity analysis indicated that the
likelihood that the DESMOND programme is cost effective
at a threshold of £20000 per QALY is 66% using trial
based intervention costs and 70% using “real world”
costs. Results from a one way sensitivity analysis suggest
that the DESMOND intervention is cost effective even
under more modest assumptions that include the effects
of the intervention being lost after one year.
Conclusion Our results suggest that the DESMOND
intervention is likely to be cost effective compared with
usual care, especiallywith respect to the real world cost of
the intervention to primary care trusts, with reductions in
weight and smoking being the main benefits delivered.
INTRODUCTION
Type 2 diabetesmellitus affects around 5%of people in
European populations and is responsible for a dispro-
portionate use of health service resources.1 In the short
term, diabetes can be accompanied by various symp-
toms such as fatigue, and in the long term it can lead to
serious complications such as blindness, renal failure,
and amputation.2 Furthermore, diabetes is associated
with increased morbidity and premature death from
cardiovascular diseases, including stroke and myo-
cardial infarction. Lifestyle advice on diet and exercise
is at the core of first linemanagement of diabetes, either
alone or with concomitant use of drugs such as
metformin.3 However, patients find it difficult to
implement and sustain lifestyle advice given by health-
care professionals.4
The national service framework for diabetes and the
2008 National Institute for Health and Clinical Excel-
lence diabetes guideline5 explicitly state that all pri-
mary care trusts should offer structured education
programmes to people with type 2 diabetes from the
point of diagnosis. The diabetes education and self
management for ongoing and newly diagnosed (DES-
MOND) intervention for peoplewith newly diagnosed
type 2diabeteswas one of the first programmes tomeet
the criteria for suitable education programmes laid
down by the National Institute for Health and Clinical
Excellence and is currently available in at least 80 pri-
mary care trusts in England and Scotland. The pro-
gramme, which is facilitated by registered healthcare
1School of Health and Related
Research (ScHARR), University of
Sheffield, Sheffield
2DESMOND Project Office,
University Hospitals of Leicester
NHS Trust, Leicester
3Academic Unit of Diabetes,
Endocrinology and Metabolism,
School of Medicine and
Biomedical Sciences, University of
Sheffield, Sheffield
4Department of Health Sciences,
University of Leicester, Leicester
5Combined Universities Centre for
Rural Health, Geraldton, Australia
6Department of Cardiovascular
Medicine, University of Leicester,
Leicester Royal Infirmary,
Leicester
Correspondence to: M Gillett
m.gillett@sheffield.ac.uk
Cite this as: BMJ 2010;341:c4093
doi:10.1136/bmj.c4093
BMJ | ONLINE FIRST | bmj.com page 1 of 10
professionals trained as educators, comprises six hours
of contact time during a full day or as two half day ses-
sions. The curriculum focuses on lifestyle factors, such
as food choices and physical activity, and cardio-
vascular risk factors.
Before the trial of the DESMOND programme,
which started in 2004,6 there was no evidence that
structured education from the point of diagnosis pro-
vides addedbenefit for patients beyondusual care. The
cluster randomised trial took place in 13 primary care
sites (162 practices) involving 1109 patients with type 2
diabetes who were referred within four weeks of diag-
nosis. A total of 824 (74%) individuals consented and
were assigned to either the DESMOND intervention
or standard care on the basis of which study arm their
practice was randomised to. Those randomised to the
intervention completed the structured group educa-
tion programme within 12 weeks. The study design,
baseline characteristics of the patients, and changes in
biomedical, lifestyle, and psychosocial measures over
12 months in the 91% of participants with follow-up
data at 12 months have been reported previously.6-8
Analyses of the trial data showed improvements in
weight, smoking cessation, illness beliefs, and depres-
sion scores in patients who received the intervention
compared with those on standard care.6
To date, there has been no economic evaluation of
theDESMONDintervention, or any similar education
intervention in theUnited Kingdom, to assess whether
the benefits reported in our trial represent a cost effec-
tive return on the intervention compared with either
no education or ad hoc and unevaluated education
(that is, usual care). This study examines the cost and
utility of the DESMOND programme when assessed
against the National Institute for Health and Clinical
Excellence’s cost effectiveness acceptability threshold
of £20 000 (€23 982; $31 191) per quality adjusted life
year (QALY),9 based on intervention costs both from
the earlier trial and as currently being implemented in
a UK primary care setting.
METHODS
The costs of delivering the DESMOND programme
and its effects on health related quality of life, particu-
larly in relation to reductions in weight and smoking,
will accrue over the long term, and, therefore, an ana-
lysis using only the 12 month outcomes from our pre-
vious trial would be inappropriate. We incorporated
the 12 month trial results into a long term model of
diabetes—the Sheffield type 2 diabetes model—that
accounts for the long term effects of the intervention
on smoking and weight as well as on the biomedical
measures (that is, levels of glycated haemoglobin
(HbA1c), cholesterol, and systolic blood pressure) that
affect comorbidities of diabetes, such as cardio-
vascular disease, retinopathy, neuropathy, and renal
complications.
The trial based inputs we planned to use in the dia-
betes model needed to take account of the clustered
nature of the data (that is, randomisation was at prac-
tice level).6 Consequently, these inputs were analysed
using robust generalised estimating equations,10 11 with
exchangeable correlation structure. For binary out-
comes, a logit link with a binomial distribution for the
outcome was used. For continuous outcomes, an iden-
tity link with a normal distribution was used. For ordi-
nal outcomes, we used an ordinal regression model
with proportional odds assumption, adjusted for
clusters.12 Aswell as adjusting for clustering, additional
covariateswere incorporated into the statisticalmodels
as deemed appropriate for the specific analyses being
undertaken. Analyses were done using STATA
10.0/SE for Windows. Missing outcomes were not
replaced and analyses were carried out on an intention
to treat basis.
The overall approach to the economic evaluation is
in line with the reference case methods for National
Institute for Health and Clinical Excellence technol-
ogy appraisals. The economic evaluation component
used an NHS and personal social services perspective
for costs, and health outcomes measured in QALYs
were based on EQ-5D values. Both costs and QALYs
were discounted at 3.5%per annum in linewith current
National Institute for Health and Clinical Excellence
guidance.9
Estimates of cost
Costs of delivering the DESMOND programme
We undertook a bottom up costing exercise to calcu-
late the average cost per patient of delivering the DES-
MOND programme within the trial (table 1). Some
items of expenditure, such as the training of educators
and non-consumable purchases for the course (for
example, food models, display boards), provided
resources for use over a much longer period than the
trial. Research costs, including one additional general
practitioner visit, were excluded from the costs of the
programme. Non-recurrent costs were spread over a
three year period using annuitisation at a rate of 3.5%
a year, with the equivalent annual cost being included
in the calculation of the cost of the course.
The costs of delivering the programme in primary
care have changed since the trial because the DES-
MOND team has a better appreciation of resource
requirements and was able to capture the economies
of scale through widespread delivery of the pro-
gramme (for example, more participants per educa-
tor). Therefore, we also estimated the “real world”
cost of the components of the programme for a
hypothetical primary care trust with an average
population of 329 550 patients. We also assumed a
total of 56 DESMOND courses would be run each
year by three educators and an average of 10 patients
per course.
Other within trial costs
Trial data were used to identify use of drugs and use of
general practitioners’ and other primary care profes-
sionals’ time over 12 months. Medication use was
recorded at four month intervals in the trial, so we esti-
mated an individual’s aggregated drug use over the
12 months of the trial from the usage recorded at
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Table 1 | Costs of the DESMOND intervention
Category and details of
cost
Level cost
incurred
Cost based on the trial of the DESMOND
intervention6 Cost in the “real world”
Cost (£) Basis Cost (£) Basis
Delivery of the DESMOND intervention
Educators DESMOND
course
531 Two educators per course for two days per
course, at £128 per day
479 One educator per course for one day
per course, at top of band 6 (£39701
per year including costs)
Refreshments Patient 4 Average of £3 per patient for a one day
courseor£1.50 if coursesplitover twodays;
scaled up to include cost of guests
(assumed ratio of patients to guests=5:3)
1 Estimate (less than during trial as no
lunch provided in “real world”)
Handbook Patient 12 — 5 —
Disposable course
materials (for example,
flipcharts, worksheets)
DESMOND
course
6 — 8 —
Course materials (for
example, food, models)
Primary care
trust*
630 — 0 Included in £675 starter pack from
DESMOND central office
Non-perishable “food
models”
Primary care
trust
Covered
within
“sundries”
cost below
— 18 —
Leaflets and postage (for
example, letter
confirming date, letter to
practice)
Patient 2 — 2 —
Venue DESMOND
course
Not
applicable
Included within £400 sundry payment to
primary care trust
25 Estimate based on feedback from
primary care trusts; can vary by a
large amount depending on local
circumstances
Sundries Primary care
trust
400 None assumed research cost 0 Itemised above
Training costs
Courses to train
educators
Trial* 30 224† Training days Included in fees (see “Programme fees
from DESMOND central office” below)
—
Sundry course resources Trial* 9 — Included in fees (see “Programme fees
from DESMOND central office” below)
—
Quality assurance of educators
Educator time and travel Not applicable 0 Quality assurance done while courses
running
Included in fees (see “Programme fees
from DESMOND central office” below)
—
Qualityassurers’ timeand
travel‡
Educator* 181 Two educators were assessed at each visit;
total 11 visits
Included in fees (see “Programme fees
from DESMOND central office” below)
—
Programme fees from DESMOND central office
Training three educators
(year one)
Primary care
trust*
Not
applicable
— 2385 £360 each for three educators per
primary care trust per year
Quality assurers’ feesand
travel (years two and
three)
Primary care
trust*
Not
applicable
— 1001 —
Annual fee for
accreditation (year two
onwards)
Primary care
trust*
Not
applicable
— 300 £50 per educator per year
Starter pack Primary care
trust*
Not
applicable
— 675 —
Programme fee§ Primary care
trust*
Not
applicable
— 4943 0.015p per patient in primary care
trust per year
Coordination and indirect costs incurred by primary care trusts
Coordination time (for
example, booking
patients on course,
sending letters, booking
rooms)
DESMOND
course
127 Expected to do five courses in trial 59 3.5 hours per course at Band 4 (£20
821 per year including costs)
Within trial central office costs (delivery only)
Element to annuitise (for
example, arranging
training)
Trial* 742 0.5 days per month for 15 months Not applicable —
Element relating to trial
period
Trial 742 — Not applicable —
DESMOND, diabetes education and self management for ongoing and newly diagnosed.
Educators’ travel costs were deemed to be negligible because these costs would not be claimed if the course was held locally or no further than the distance to workplace.
*The benefits of these resources accrue over several years. We conservatively spread out such costs over a period of three years.
†£30<thin>224 was the cost of training 26 educators on two courses. The courses took two days and were necessarily residential to allow participation of educators from all over the country.
This outlay contributed £69 towards the cost per patient of delivering the DESMOND course during the trial (including overheads).
‡For the trial, this cost was averaged across 13 primary care trusts because not all trusts received a quality assurance visit.
§Dependent on size of primary care trust. Total calculated from average primary care trust size.
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baseline,month four,month eight, andmonth 12.Unit
costs of drugs were obtained from the NHS Informa-
tion Centre for Health and Social Care’s prescription
cost analysis 200713 and aweighted average of themost
frequently used drugs in each class was used. Unit
costs for visits to a general practitioner and other
consultations were obtained from the Personal Social
Services ResearchUnit’s unit costs of health and social
care 2007.14
Differences between the control and the inter-
vention group in drug use and use of NHS resources
are shown in table 2. These costs were then combined
and reanalysed to adjust for clustering and covariates
that were relevant to both drug and resource.
Unit costs relating to long term complications
Unit costs relating to long term complications were
obtained from a variety of published sources, the
most significant ones for this evaluation being costs of
events relating to cardiovascular disease and comor-
bidities, which were obtained from United Kingdom
Prospective Diabetes Study number 65 (UKPDS
65).15 These data were adjusted to 2008 levels using
the Hospital and Community Health Services Pay
and Price Index.14
Effects of the intervention at month 12 of the trial
Biomedical measures
In the long termmodel described later, the differences
between biomedical measures at baseline and these
characteristics at 12 months in the trial of the
DESMOND intervention were incorporated into the
characteristics of patients at baseline, as shown in
table 3. Lifestyle changes might not be sustained with-
out an ongoing maintenance intervention, so we
assumed that the effects observedwould be completely
lost three years after the end of the intervention.
Smoking
Smoking status at entry to the long term model was
basedon the conditional probabilities shown in table 4,
which relate final smoking status in the trial of theDES-
MOND intervention to that at baseline. This shows
that, compared to patients in the control arm, there
was a greater probability of patients in the intervention
armstopping smoking, and less chanceof non-smokers
starting smoking. We obtained annual relapse rates
from an analysis16 of British Household Panel Survey
data and used these to model the probability that a
patient who had quit smoking during the trial subse-
quently relapses. We calculated a relapse rate of
19.6% after one year of abstinence, which decreases
to 3.8% at five years and 1.6% at 12 years.
Weight
After adjustment for age, gender, HbA1c, smoking sta-
tus, use of drugs known to affect weight (for example,
oral hypoglycaemic agents, diuretics), baseline values,
and clustering, there was a −1.26 kg (95% CI −2.19 to
−0.34) difference in weight between the intervention
arm and the control arm at 12 months. This effect
may not be sustainedwithout an ongoingmaintenance
Table 2 | Use of medication and NHS resources in the trial of the DESMOND intervention, unit costs, and overall cost
differences
Control (unadjusted)
Intervention
(unadjusted)
Adjusted difference*
(mean (95% CI)) Unit cost (£ per day)
Effect of difference in
usage on cost (£)
Medication use (average number of months use per patient during the 12 months of the trial)
Metformin 3.04 3.30 −0.35 (−0.92 to 0.22) 0.1313 −1.38
Sulphonylureas 0.80 0.79 −0.15 (−0.48 to 0.18) 0.1113 −0.50
Glitazones 0.20 0.20 −0.08 (−0.22 to 0.06) 1.1413 −2.77
Lipid lowering drugs 7.05 7.29 −0.17 (−0.87 to 0.53) 0.3013 −1.55
Antihypertensive drugs 7.50 7.21 −0.04 (−0.48 to 0.40) 0.1413 −0.17
Aspirin 4.43 4.45 0.21 (−0.43 to 0.84) 0.0413 0.26
Antidepressants 1.11 1.02 0.10 (−0.15 to 0.34) 0.0313 0.09
TOTAL −6.03
Use of NHS resources (mean number of visits)
General practitioner 4.34 4.33 0.36 (−0.29 to 1.0) 3014 10.80
Nurse 4.82 5.26 0.25 (−0.45 to 0.94) 814 2.00
Physiotherapist 0.81 0.43 −0.35 (−0.82 to 0.11) 1614 −5.60
Podiatrist 1.36 1.23 −0.19 (−0.73 to 0.35) 914 −1.71
Dietitian 0.61 0.49 −0.15 (−0.36 to 0.07) 3714 −5.55
Optician 1.25 1.28 0.10 (−0.09 to 0.28) 38.3537 3.80
TOTAL 3.74
DESMOND, diabetes education and self management for ongoing and newly diagnosed.
*Intervention less control. Medication use calculation adjusted for clustering, baseline medication use, and corresponding baseline biomedical
measure (glycated haemoglobin (HbA1c) for oral hypoglycaemic agents; total cholesterol to high density lipoprotein cholesterol ratio for lipid lowering
drugs; systolic blood pressure for antihypertensive drugs). Use of NHS resources adjusted for clustering, age, sex, ethnicity, and baseline covariates
(body weight, smoking, HbA1c, systolic blood pressure, lipid ratio, waist circumference, BMI, and use of oral hypoglycaemic agents, antihypertensive
drugs, lipid lowering drugs, and antidepressants.
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intervention, so we assumed that it was completely lost
three years after the end of the intervention.
Drug use
The odds ratio for using an oral hypoglycaemic agent
at month 12 was 0.79. This was used to apply differen-
tial rates of oral hypoglycaemic agent use to the two
treatment arms in the long term model. We assumed
that the first line oral hypoglycaemic agent is metfor-
min, after which a sulphonylurea is added, followed by
switching to insulin plus metformin. Given that there
was negligible difference between study arms in the
rate of statin use at month 12 of the trial (odds
ratio=0.99), we applied the same rate (75%) at baseline
to the two arms in the long term model. There was a
higher rate of antihypertensive therapy use at month
12 in the intervention arm, but this difference was not
statistically significant (odds ratio 1.18, 95% CI 0.71 to
1.98). This equates to only 4%higher usage in the inter-
vention arm, equivalent to an additional cost of about
£2, so we assumed equal rates of antihypertensive use
in the long term model.
Health related quality of life
Health related quality of life data were recorded from
trial participants using the EQ-5D questionnaire at
baseline and at four, eight, and 12 months. The EQ-
5Dquestionnaire uses five dimensions of health (mobi-
lity; self care; usual activities; pain and discomfort; and
anxiety and depression), each of which is assessed by a
single question and scored on a three point ordinal
scale (no problems; some problems; or extreme pro-
blems). We combined the five dimension scores at
each time period into a single preference score using
the standard UK algorithm.17 The incremental gain in
QALYs during the trial in patients who received the
DESMOND intervention was 0.0070 (95% CI
−0.0126 to 0.0491)
The decrements in health related quality of life attri-
butable to diabetes and complications of diabetes that
we used in the long termmodel were based onUKPDS
data where possible,18 with values for additional
comorbidities obtained from Coffey et al.19 Utility
changes associated with weight gain were based on a
simple weighted average of two studies20 21—a 0.0025
(95% CI 0.0003 to 0.0048) utility decrement per kg
increase in weight. A recent review of weight and
health related quality of life in patients with or without
type 2 diabetes reported similar results.22
Long term modelling
The Sheffield type 2 diabetes model is an integrated
individual level simulation model23 that estimates—
using changes in key risk factors such as smoking sta-
tus, HbA1c level, lipid concentration, and blood pres-
sure—the effect of alternative interventions on long
term incidence of diabetic complications and mortal-
ity, and the associated economic effects of such inter-
ventions and outcomes. The model also includes side
effects such as hypoglycaemic attacks and, importantly
for this assessment, the ability to estimate the effect of
weight changes on health related quality of life. A
description of the Sheffield type 2 diabetes model and
a model structure diagram appear in web extra 1 and
web figure A, respectively.
The main outcome in our long term modelling was
the incremental cost perQALY gained in patients who
received the DESMOND intervention compared with
those who received usual care. The time limit used for
the long term modelling was 80 years (effectively life-
time for this age group).
The UKPDS coronary heart disease and stroke risk
engines use smoking status at diagnosis of diabetes as a
risk factor.24 25We assumed that current smoking status
can be applied in these equations so that ongoing risk
estimates of cardiovascular disease take account of
changes in smoking status. Comparison of the hazard
ratios from these risk engines with those from the
UKPDS outcomes model26 (which uses current smok-
ing status) suggests that this is a reasonable assumption.
The effect of smoking on other cause mortality was
based on the hazard ratio reported in the UKPDS out-
comes model.
The mean characteristics of patients at entry to the
long term model are shown in table 5 and reflect the
mean adjusted differences between the intervention
and the control (that is, adjustment was made to elim-
inate differences at baseline between the two study
arms of the trial). Prevalence of atrial fibrillation was
not obtained from the DESMOND data but assumed
to be 1% on the basis of UKPDS data.
Uncertainty and sensitivity analyses
The approach to the handling of uncertaintywas essen-
tially Bayesian, with values being sampled from distri-
butions for parameters (for example, HbA1c level,
weight) to capture uncertainty around the mean esti-
mates. A probabilistic sensitivity analysis was con-
ducted by combining 500 random samples from the
Table 3 | Difference between control and intervention in biomedical markers of cardiovascular
disease at 12 months in the trial of the DESMOND programme
n
Mean (95% CI) cluster adjusted difference
(intervention − control)
HbA1c (%) 715 0.060 (−0.097 to 0.217)
Total cholesterol (mmol/l) 709 −0.044 (−0.201 to 0.114)
High density lipoprotein cholesterol (mmol/l) 526 0.015 (−0.043 to 0.073)
Systolic blood pressure (mm Hg) 727 0.984 (−1.800 to 3.768)
DESMOND, diabetes education and self management for ongoing and newly diagnosed; HbA1c, glycated
haemoglobin.
Table 4 | Likelihood of smoking at month 12 given baseline smoking status in the trial of the
DESMOND programme
Conditional probability that individual smokes at month 12 (mean
(95% CI))
Control Intervention
Smoker at baseline 0.882 (0.774 to 0.990) 0.861 (0.748 to 0.974)
Non-smoker at baseline 0.037 (0.010 to 0.064) 0
DESMOND, diabetes education and self management for ongoing and newly diagnosed.
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trial results, obtained using bootstrapping, with 500
sample results from probabilistic sensitivity analysis
eachwith a cohort size of 100 patients.27 This approach
assumes that the incremental costs during the trial were
independent of incremental costs from the long term
model; likewise for incremental QALYs gained. This
assumption was considered reasonable because eco-
nomic outcomes arising during the trial are strongly
driven by the effect of undertaking lifestyle changes
during the trial, whereas economic outcomes from
the long term model are more complex, with results
being more driven by uncertainty in model para-
meters, such as the coefficients used in the cardio-
vascular risk equations. Probabilistic sensitivity
analyses were undertaken using both trial and real
world costs of delivering theDESMONDprogramme.
We also undertook a sensitivity analysis using more
conservative assumptions, in particular concerning the
durability of the effects of the DESMOND inter-
vention observed at the end of the trial. Changes in
biomarkers (including weight) were assumed to last
for only one year from the end of the trial, smoking
relapse rates were scaled up by 25%, and a lower
hazard ratio was assumed for other cause mortality
due to smoking (1.24 v 1.36 for the base case analysis).
RESULTS
On the basis of our costing exercise, the estimated cost
of delivering the DESMOND programme in the
12month trial of the interventionwas £203 per patient.
The equivalent real world cost per patient for a
hypothetical primary care trust was estimated to be
£76. Costs would vary, however, depending on local
circumstances (for example, population size, pay scales
of staff, number of staff trained). The cost of the DES-
MOND programme in terms of its effect on drug use
and use of NHS resources was £16 in the trial, which
differs from the sum of the two individual components
shown in table 2 because of adjustment for clustering
and covariates that were relevant to both drug and
resource. Adding this value to the £203 cost of the
intervention during the trial gives an estimated
12 month total incremental cost for the DESMOND
intervention arm of £219. Using the £76 real world
cost of the intervention, the total incremental cost
was £92.
The results from the economic modelling are shown
in table 6.Modelled lifetime costs—which incorporate
drug costs, monitoring, and costs of complications
from the end ofmonth 12 to 80 years—are almost iden-
tical at £15 836 in the control arm and £15 826 in the
intervention arm, a difference of just £10 (discounted).
Therefore, the total lifetime cost of patients receiving
the DESMOND intervention is £16 289 using trial
based intervention costs and £16 162 using real world
costs, £209 (95% confidence interval −£704 to £1137)
and £82 (−£831 to £1010) more expensive than usual
care, respectively.
The mean cluster adjusted gain in QALY with the
DESMOND programme up to month 12 in the trial
is estimated at 0.0070, equivalent to an average gain
of 2.55 days of perfect health per person over the
year. The long term gain in QALYs (end of month 12
to remaining lifetime) is estimated at 0.0322, so the
total estimated gain in QALYs for patients who
received the DESMOND intervention compared
with those who received usual care was 0.0392—
equivalent to a discounted average gain of 14.2 days
of perfect health per person over their lifetime. The
estimated incremental cost per QALY gained is
Table 5 | Characteristics derived from measures at month 12 of the trial of the DESMOND
intervention that were used as inputs for the long term model
Control (mean (SD) or
n/N (%))
Intervention (mean (SD) or
n/N (%))
Age (years) 61 (12) 61 (12)
Sex (proportion male) 26 910/50 000 (54) 26 910/50 000 (54)
Smoking status (proportion who
smoke)
8129/50 000 (16.3) 6294/50 000 (12.6)
High density lipoprotein cholesterol
(mmol/l)
1.231 (0.385) 1.246 (0.385)
Total cholesterol (mmol/l) 4.440 (0.967) 4.399 (0.967)
Systolic blood pressure (mm Hg) 133.74 (15.55) 134.72 (15.55)
HbA1c level (%) 6.64 (0.96) 6.70 (0.96)
Ethnic origin
White 48 623/50 000 (97) 48 623/50 000 (97)
African-Caribbean 467/50 000 (1) 467/50 000 (1)
Indian 910/50 000 (2) 910/50 000 (2)
Time since diagnosis (years) 1 (0) 1 (0)
Former smoker at diagnosis 20 010/50 000 (40) 20 543/50 000 (41)
Therapy at entry
Diet and exercise 29 868/50 000 (59.7) 31 032/50 000 (62.1)
Metformin 16 283/50 000 (32.6) 15 447/50 000 (30.9)
Metformin and sulphonylurea
combination
3849/50 000 (7.7) 3521/50 000 (7.0)
DESMOND, diabetes education and self management for ongoing and newly diagnosed; HbA1c, glycated
haemoglobin.
Age and gender are the same in each arm because the aim of the modelling was to compare the long term
effects of the DESMOND programme with the effects of the control intervention in the same cohort.
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Fig 1 | Cost effectiveness acceptability curves for the
probability that the diabetes education and self management
for ongoing and newly diagnosed (DESMOND) programme is
more cost effective than usual care. The curves relate to the
combined trial and long term modelling results, and are based
on the cost of the DESMOND intervention during the trial and
in the real world. The vertical dotted lines show the cost
effectiveness acceptability thresholds of £20000 per QALY
and £30000 per QALY
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£5387 using trial based intervention costs and £2092
using real world costs. Such estimates are well within
the threshold of £20 000 to £30 000 per QALY usually
considered by the National Institute for Health and
Clinical Excellence and other bodies as cost effective.
Uncertainty analysis
The cost effectiveness acceptability curves (fig 1) show
that the probability of the DESMOND programme
being more cost effective than usual care is fairly simi-
lar whether trial or real world intervention costs are
used. Using trial costs, the probability of the DES-
MOND programme being more cost effective than
usual care is 0.66 for an acceptability threshold of
£20 000 per QALY (0.68 for a threshold £30 000 per
QALY). Using real world costs, the probability is 0.70
for both an acceptability threshold of £20 000 and a
threshold of £30 000 per QALY. The probability of
the DESMOND programme being cost saving in the
long term is 0.28 using trial costs and 0.40 using real
world costs. The probability of the DESMOND pro-
gramme resulting in long term gains in QALYs is 0.70
and 0.71 using trial and real world costs, respectively.
The probabilistic sensitivity analysis results pre-
sented in figure 2 show the spread of the real world
cost effectiveness estimates on a plane. Although
neither the mean incremental cost nor the mean incre-
mental QALYs reach an arbitrary 5% significance
level, the probability of an intervention being cost
effective is determined froma joint assessment of incre-
mental costs and incremental QALYs. On the plane,
70% of the sampled data lie within the cost effective
region to the right of the cost effectiveness “frontier,”
indicating a probability of the DESMOND inter-
vention being cost effective of 0.7.
Sensitivity analysis
The sensitivity analysis, which adopted amore conser-
vative assumption relating to the durability of the
effects observed at the end of the trial and a lesser effect
of smoking on other cause mortality, did not change
the results substantially. The incremental cost per
QALY using the real world intervention costs was
actually marginally lower than in the original analysis,
at £1618 comparedwith £2092, with a 0.71 probability
of cost effectiveness.
DISCUSSION
Principal findings
Taking account of simulated longer term effects, there
is a 66% likelihood that the DESMOND intervention
as delivered during the trial of the intervention is cost
effective. Furthermore, the intervention is even
cheaper as currently implemented in the real world,
costing £76 per patient compared with £203 each in
the trial. This disparity is a result of economies of
scale and some unavoidable high costs during the
trial (for example, residential courses were required
to train educators attending from across the country).
As such, the likelihood that the DESMOND pro-
gramme is cost effective in the real world is, at 70%,
higher than in the trial. When the analysis was
restricted to the costs and benefits within the
12month time frameof the trial, theDESMONDinter-
vention does not appear to be cost effective, as is often
the case for an intervention aimed at preventing the
long term effects of a chronic disease, although there
is much uncertainty around the results.
Our results suggest that the DESMOND inter-
vention is likely to be cost effective compared with
usual care, especially with respect to the current cost
of the intervention to primary care trusts. However,
concluding that the intervention is likely to be cost
effective despite the relatively small (and not all statis-
tically significant) trial outcomes in terms of between
group differences is at first sight counterintuitive. In
order to make this conclusion, it is necessary to take
into account both the size and the likelihood of health
Table 6 | Economic evaluation of the DESMOND intervention compared with usual care
(control) using trial based costs and “real world” costs
Control DESMOND intervention
Difference: intervention −
control (95% CI)
Intervention costs up to month 12
Trial based intervention cost — £203 £203
“Real world” intervention cost — £76 £76
Other resource use (per within
trial analysis)
£244 £260* £16 (−£24 to £56)
Remaining lifetime discounted costs
Therapy and monitoring £5286 £5302 £17
Complications £10 445 £10 419 −£26
Adverse events (for example,
oedema, hypoglycaemic
attacks)
£105 £104 −£1
Subtotal: remaining lifetime
costs
£15 836 £15 826 −£10
Combined total lifetime costs
Trial based total costs £16 080 £16 289 £209 (−£704 to £1137)
“Real world” total costs £16 080 £16 162 £82 (−£831 to £1010)
QALY gain up to month 12 0.7530 0.7600† 0.0070 (−0.0126 to
0.0491)
Discounted QALYs in remaining lifetime
Mean QALYs lived if not diabetic 13.9195 13.9195 0
QALYs lost because of reduced
survival related to diabetes
−4.2809 −4.2526 0.0283‡
QALYs lost because of
complications of diabetes
−0.3835 −0.3833 0.0002
Weight related change in QALYs −0.0447 −0.0410 0.0037
Subtotal: QALYs in remaining
lifetime
9.2104 9.2426 0.0322
Combined total QALYs gained in
lifetime
9.9634 10.0026 0.0392 (−0.0813 to
0.1786)
Incremental cost per QALY gained
Trial based total costs — — £5387
“Real world” total costs — — £2092§
DESMOND, diabetes education and self management for ongoing and newly diagnosed; QALY, quality adjusted
life year.
*Other resource use shown as actual cost in control arm plus £16 for the cluster adjusted difference between
study arms.
†QALY gain up to month 12 shown as actual QALYs in control arm plus 0.0070 for the cluster adjusted
difference between study arms.
‡Difference in QALYs lost because of reduced survival related to diabetes attributable mostly to the net effect of
differences in smoking on other cause and cardiovascular mortality.
§See the cost effectiveness plane in figure 2[F2] for the distribution of cost effectiveness estimates.
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gains. Firstly, the nature of the intervention should be
taken into account—that is, the DESMOND pro-
gramme targets multiple risk factors. As such, it is the
overall benefit of what are often small changes that
needs to be considered. The collectivemean estimated
benefit of the changes arising from the DESMOND
intervention is sufficient to outweigh the low inter-
vention cost per patient. Indeed, the estimated mean
health gains as measured by QALYs gained are
equivalent to half a month of full health, an economic-
ally adequate return for a low cost investment. In other
disease areas, treatments can cost tens of thousands of
pounds per patient for the equivalent of severalmonths
QALY gains. Secondly, the likelihood of the inter-
vention being cost effective, in this case 70%, reflects
the methods of economic evaluation, which, rather
than focusing on type 1 or type 2 errors, consider the
costs and health gains simultaneously.
The most economically significant benefits of the
DESMOND programme are reductions in overall
cardiovascular risk (mainly resulting from reduced
smoking rates, as shown in table 4, but also improve-
ments to lipids, as shown in table 3), leading to greater
survival. Together with a reduction in weight, these
benefits lead to economically significant gains in
QALYs (as shown in table 6).
It is interesting that the sensitivity analysis reduced
the cost of the DESMOND programme per QALY
gained. One might expect the more conservative set
of assumptions used in the sensitivity analysis to
increase rather than decrease the intervention cost
per QALY gained. The main reason for this slightly
counterintuitive result is that the more conservative
assumptions reduce the incremental cost difference
between the intervention and control arms. This is
because, in the sensitivity analysis, a lower hazard
ratio was assumed for other cause mortality due to
smoking, resulting in extended survival in both study
arms. The additional survival benefit was greater in the
control patients as there were more smokers in this
arm, resulting in greater exposure to the risk of com-
plications, which require costly treatments.
Strengths and limitations of the study
Our analysis uniquely represents a detailed long term
economic evaluation of a structured education pro-
grammebased on results fromaUKbased randomised
controlled trial that was carried out in accordance with
a robust evaluation framework.28 Given that this was a
largemulti-site trial, the results aremore representative
than if we had used single centre studies.
The main areas of uncertainty around the results
concern the effect of smoking onmortality and the dur-
ability of benefits such as improved rates of smoking
and weight loss. For some risk factors used in the long
termmodel, the differences between treatment groups
were relatively small or were not statistically signifi-
cant. Nevertheless, uncertainty around such effects is
captured within the results of the probabilistic sensitiv-
ity analysis, and the benefits reported are economically
significant when set against the low cost of the inter-
vention. Furthermore, a sensitivity analysis that
assumed the benefits only last for one year beyond
the end of the 12 month trial and applied a lesser effect
of smoking on mortality still showed a 71% likelihood
that the intervention is cost effective.
Comparison with other studies
There are few other studies against which meaningful
comparisons canbemadebecause of the heterogeneity
of the interventions across studies (for example, differ-
ent amounts of education provided by various health
professionals; different timing of the intervention rela-
tive to diagnosis of diabetes) and lack or limitations of
economic evaluations in type 2 diabetes.
A review for the National Institute for Health and
Clinical Excellence on the use of patient education
models29 reported an evaluation of the Dose Adjust-
ment For Normal Eating (DAFNE) intervention for
type 1 diabetes. The review concluded that the inter-
vention is both cost saving and generates health bene-
fits comparedwith conventional treatment, evenunder
modified conservative assumptions adopted by the
technology assessment group. A recent review of the
clinical effectiveness of diabetes education models for
type 2 diabetes30 describes two studies in the United
States thatwere considered to be limited in their applic-
ability and generalisability. The review did not draw
any conclusions on the overall cost effectiveness of
the education models. Another recent review focusing
on the cost effectiveness of diabetes education31 refers
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Fig 2 |Cost effectiveness plane for the combined trial and “real
world” costs of the diabetes education and self management
for ongoing and newly diagnosed (DESMOND) programme.
Solid points represent incremental cost and QALY results
(intervention arm minus control arm) from the probabilistic
sensitivity analysis for each of the 500 samples. The dashed
horizontal and vertical blue lines show the 95% confidence
interval for the incremental costs and the 95% confidence
interval for the incremental gains in quality adjusted life
years. The blue curve is the 95% confidence ellipse. All points
to the right of the diagonal dashed red line, or “frontier,” are
cost effective at an acceptability threshold of £20000 per
quality adjusted life year
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to several economic studies involving differing
amounts of education provided by various health
professionals. The authors conclude that diabetes
education is likely to be cost effective, especially
when provided to patients with the poorest
glycaemic control.
Two other well known diabetes education studies,
theTurin study32 and theExpert PatientEducationver-
sus Routine Treatment (XPERT) programme,33
assessed patients with established type 2 diabetes.
However, economic evaluations of these studies have
not been undertaken. The need to offer optimal inter-
vention from diagnosis in patients with diabetes is sup-
ported by the legacy effect observed from the long
term follow-up data of the UKPDS.34
Unanswered questions and future research
Although it is likely that the one off DESMOND inter-
vention is cost effective, it must be noted that the DES-
MOND programme was never intended as a one off
intervention. An ongoingmodel of education and care
is currently being developed, which will provide rein-
forcement at additional points of contact and an opti-
mal environment for improving patient outcomes
from education, as discussed by Loveman and
colleagues.30 Diabetes prevention trials have shown
that with reinforcement, benefits such as weight loss
can be sustained over a period of several years inmany
patients.35
The independent effects of some changes in biome-
dical and other measures on health related quality of
life (and comorbidities) are unknown.For example, the
DESMOND programme had a favourable effect on
symptoms of depression, as measured by the hospital
anxiety and depression (HADS) score. It is likely that
this effect would result in some economic benefits
beyond the trial that are not included in our results;
for example, in terms of reduced use of health care,
improved quality of life, or both. In addition, the inter-
vention group also achieved a greater fall in triglycer-
ide concentration atmonth12 than the control group (a
measure that is not capturedwithin theUKPDScardio-
vascular disease risk equations) and a more positive
change in illness beliefs about diabetes (although the
extent to which this is captured by utility instruments
such as the EQ-5D warrants further investigation).
No significant effect of theDESMOND intervention
on the amount of time spent with healthcare profes-
sionals was observed during the trial. Potentially,
improved skills in self care might reduce the need for
patients with diabetes to seek advice fromNHSprofes-
sionals, although an increased awareness following
participation in the DESMOND programme might
help patients make better use of opportunities for
advice seeking and more appropriate visits to primary
healthcare clinicians, as well as improve compliance
with drug and prescribed therapies.
As with other lifestyle programmes, such as those to
prevent diabetes, there will be considerable variability
across patients in their response to the DESMOND
intervention. Greater understanding of how to lessen
physiological andmotivational barriers in non-respon-
sive individuals would help to improve the effective-
ness of the intervention in a broad mix of patients.
The real world costs of delivering the DESMOND
programme are likely to vary considerably across pri-
mary care trusts. The main variables affecting the cost
are the number of educators trained, the grade of
healthcare professional delivering courses, venue
cost, ratio of demand to head of population (including
participation rate), number of patients per course, and
overhead rates. There is a continuum of delivery costs
associated with delivering the intervention, ranging
from running the intervention extremely efficiently
(for example, training a small number of educators
and having them deliver the DESMOND programme
full time) to running it less efficiently (for example,with
a high ratio of educators to course sessions). These fac-
tors need to be considered when setting up a cost effec-
tive DESMOND programme.
Conclusions and policy implications
We conclude, on the basis of the results of a rando-
mised controlled trial of the intervention and estimated
costs of delivery in the real world, that theDESMOND
programme is a low cost and likely cost effective inter-
vention for patients with newly diagnosed type 2 dia-
betes. People attending DESMOND sessions are
encouraged to decide on their own goals, which often
include weight loss and smoking cessation. These out-
comeswere both significantly improved in the trial and
were the most important drivers in the economic ana-
lysis. Although HbA1c level was not improved in the
trial of the DESMOND intervention, this may have
been because the major improvements in HbA1c
level achieved in the period after diagnosis of diabetes,
as seen inboth study arms,mayhavemasked any effect
WHAT IS ALREADY KNOWN ON THIS TOPIC
The diabetes education and self management for ongoing and newly diagnosed (DESMOND)
intervention for people with newly diagnosed type 2 diabetes is a one off education
programme that meets all the quality criteria for education programmes specified by the
National Institute for Health and Clinical Excellence
The DESMOND programme has been shown to be associated with benefits in illness beliefs,
weight loss, physical activity, smoking status, and depression but not in haemoglobin A1c
levels
To date, there has been no economic evaluation of the DESMOND intervention to assess
whether the benefits reported in the previous trial represent a cost effective return for the
programme compared with usual care
WHAT THIS STUDY ADDS
The cost of delivering the intervention is estimated at £203 per patient on the basis of costs
in the previous trial and £76 on the basis of “real world” costs estimated for a hypothetical
primary care trust
The estimated incremental cost per quality adjusted life year (QALY) gained is £5387 using
the trial based costs and £2092 using real world costs
The probability that the DESMOND intervention is cost effective in the long term using a cost
effectiveness acceptability threshold of £20000 (€23982; $31191) per QALY is 0.66 for trial
based costs of delivery and 0.70 for real world costs
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of the intervention.36 Maintenance of these benefits is
important for reducing the risk of cardiovascular dis-
ease and improving quality of life. Our analysis indi-
cates that the DESMOND programme is likely to be a
cost effective form of structured education that should
be given in line with National Institute for Health and
Clinical Excellence guidance.5
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